Press release
SIGA Technologies, Inc. Reports Financial Results for Three and Six Months Ended June 30, 2020
- Second Quarter includes Deliveries to SNS and First International Delivery - - Corporate Update Conference Call Today at 4:30 PM ET - NEW YORK, Aug. 06,
About this update from Siga Technologies Inc.
[{"type":"text","content":"- Second Quarter includes Deliveries to SNS and First International Delivery -\n - Corporate Update Conference Call Today at 4:30 PM ET - NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today reported financial results for the three and six months ended June 30, 2020. “SIGA’s successful second quarter was highlighted by the initial deliveries of TPOXX® to the U.S. Strategic National Stockpile pursuant to the April option exercises and to the Canadian Department of Defence, as part of our first international order,” said Phil Gomez, CEO of SIGA. “In addition to our strong financial results, we are laying the groundwork for the future; We recently submitted a Marketing Authorisation Application for oral tecovirimat with the European Medicines Agency in July, and are targeting regulatory submissions within the next six months to Health Canada for oral TPOXX, as well as a New Drug Application for the IV formulation of TPOXX to the FDA. Furthermore, we are preparing clinical protocols to support the potential expansion of the oral TPOXX label in the U.S. to include Post-Exposure Prophylaxis, a program we are developing with funding from the U.S. Department of Defense.” Summary Financial Results ($ in millions, except per share amounts) Three Months Ended June 30, 2020 in comparison to Three Months Ended June 30, 2019 Three Months Ended June 30, 2020 Three Months Ended June 30,2019Total Revenues Operating Income (Loss) (1) Income (Loss) before Income Taxes (1) Net Income (Loss) Diluted Income (Loss) per Share $40.3 $28.8 $27.2 $20.9 $0.26 per share $3.9 ($1.7) ($4.3) ($3.2) ($0.05) per share Six Months Ended June 30, 2020 in comparison to Six Months Ended June 30, 2019 Six Months Ended June 30, 2020 Six Months Ended June 30, 2019Total Revenues Operating Income (1) Income (Loss) before Income Taxes (1) Net Income (Loss) Diluted Income (Loss) per Share $43.0 $24.8 $15.6 $12.0 $0.15 per share $14.4 $0.5 ($2.1) ($1.5) ($0.06) per share (1) Operating Income excludes, and Income (Loss) before Income Taxes includes, costs in connection with the retirement of the Company’s term loan, interest expense, interest income and adjustments to the fair value of the Company’s outstanding warrant. Both line items exclude the impac...